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Background. Traditional cardiovascular risk factors and
uremia-related specific factors have been identified in patients
with CKD, explaining the highest risk for morbidity and mor-
tality from cardiovascular disease. The aim of this study was
to analyze the predictive power of several cardiovascular risk
factors and markers in a population of stable patients with mod-
erate CKD.
Methods. One hundred twenty-eight (78 M, 50 F) outpatients
with estimated glomerular filtration rate (GFR) <60 mL/min
were included in the study. Medical records about cardiovas-
cular factors were recorded. Analytical parameters and cardiac
markers were analyzed. The patients were prospectively fol-
lowed, and the end points were fatal and nonfatal cardiovascu-
lar events.
Results. After a mean follow-up of 22.3 months, 27 patients
had a cardiovascular event. The patients who suffered a car-
diovascular event were older (P = 0.002), with more anemia
(P = 0.014), higher pulse pressure (P = 0.011), and cTnT lev-
els (P = 0.000). In addition, they had more prevalence of LVH
(P = 0.001), diabetes (P = 0.013), previous coronary heart dis-
ease (P = 0.008), chronic heart failure (P = 0.000), vascular
peripheral disease (P = 0.006), and had also a higher score of
10-year coronary heart disease predicted risk (P = 0.006). Age
[hazard ratio (HR) 1.07, P = 0.02], previous coronary artery
disease (HR 4.08, P = 0.0012), and cTnT levels (HR 1.64, P =
0.0000) independently predicted cardiovascular events on mul-
tivariate Cox analysis.
Conclusion. In stable patients with CKD, age and previous
coronary artery disease were the traditional cardiovascular risk
factors more predictive for cardiovascular events. Cardiac tro-
ponin T is a powerful marker of cardiovascular events in CKD
patients.
Patients with chronic kidney disease (CKD) are
at significantly increased risk for both morbidity and
mortality from cardiovascular disease (CVD) [1, 2].
Traditional risk factors, described primarily in the Fram-
ingham population, include, among others, hyperten-
sion, smoking, diabetes, dyslipidemia, left ventricular
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hypertrophy, and male sex. Although patients with CKD
have a high prevalence of many of these traditional
risk factors, they also are exposed to nontraditional, or
uremia-related, risk factors (anemia, altered calcium-
phosphorus metabolism, inflammation, oxidative stress,
and others) that increase in prevalence as kidney func-
tion declines [3]. At the actual moment, several cardio-
vascular markers have been identified in CKD patients
(e.g., C-reactive protein, carotid intima-media thickness,
asymmetric-dymethilarginine) [4, 5].
Several studies have shown that even moderate CKD
is associated with higher mortality rates from CVD;
however, only a few epidemiologic studies are available
about the predictive factors and markers of cardiovascu-
lar events in patients with moderate CKD.
The aim of this study was to analyze which factors and
other parameters are predictive of cardiovascular events
in a group of stable patients with moderate CKD.
METHODS
In this cross-sectional study, we included 128 consec-
utive outpatients with estimated glomerular filtration
rate (GFR) <60 mL/min who attended in a nephrology
clinic from January to May 2002. The exclusion crite-
ria were any cardiovascular events occurring within a
period of 3 months before the start of the study. The
medical records of each patient were examined by a
nephrologist.
Prevalent diseases, weight and height, body mass index
(BMI), blood pressure, lifestyle habits, and use of antihy-
pertensive and lipid-lowering drugs were recorded.
Cardiovascular risk factors and markers evaluated
were: age, gender, renal function, pulse pressure, ane-
mia, dyslipidemia, disturbances of calcium and phosphate
metabolism, albuminuria, serum albumin, cardiac tro-
ponin T levels, and left ventricular hypertrophy (LVH).
Clinical cardiovascular disease was considered if the
patient had a myocardial infarction, coronary revascular-
ization (by coronary artery bypass graft or percutaneous
transluminal coronary angioplasty), or angina pectoris.
Congestive heart failure (CHF) was diagnosed by x-ray
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examination (pulmonary edema) and echocardiogram
with left ventricular dysfunction. This diagnostic was con-
sidered because the patients were symptomatic and in
New York Heart Association (NYHA) class II-IV with
a left ventricular ejection fraction ≤45%. Cerebrovascu-
lar disease was established if the patient had a history of
transient ischemic attacks, whenever stroke could be ver-
ified by computer tomography or carotid artery stenosis
>70% could be verified by Doppler ultrasound. Periph-
eral vascular disease (PVD) was diagnosed by intermit-
tent claudication, stenosis of the major arteries of the
lower limbs proven angiographically or sonographically,
and the presence of ulcers caused by atherosclerotic dis-
ease or by surgery was used for diagnosis. Hypertension
was associated with the use of antihypertensive drugs or
with a blood pressure ≥140/90 mm Hg.
All patients were examined by electrocardiography.
We chose electrocardiogram (ECG) criteria for LVH di-
agnosis. LVH was established by mean of a Sokolow-Lyon
voltage >35 mm, and a product of QRS duration and Cor-
nell voltage >2440 mm × ms (adjusted to 8 mm in female
patients).
The 10-year absolute risk of developing coronary heart
disease (CHD) was derived from following the risk-
prediction algorithm of the Framingham model, and by
using a point score sheet. The risk prediction for CHD
was based on categorical variables such as age, sex, blood
pressure, smoking history, total and high-density lipopro-
tein (HDL) cholesterol, and diabetes history [6].
Analytical methods
Routine clinical and biochemical variables were mea-
sured by standardized methods on autoanalyzers. cTnT
was determined on sera using the ELECSYS system with
cTnT stat cardiac T reagents (both from Roche Diag-
nostics, Mannheim, IN, USA). In this third-generation
immunoassay, the capture and detection antibodies show
no cross-reactivity with skeletal cTnT. This assay is an
electrochemiluminescence immunoassay, or ECLIA. Its
detection limit is 0.01 ng/mL, and 0.1 ng/mL is recom-
mended as clinical threshold, and above this level damage
to the myocardium can be assumed to have occurred.
To measure renal function, estimated glomerular filtra-
tion rate (GFR) using the Cockroft-Gault formula was
used.
Blinding
The laboratory researcher was unaware of the baseline
clinical status of the patients. The clinical data, including
baseline and outcome status of the patient, were recorded
by the clinicians, who were unaware of the laboratory
results. The blinding was realized by keeping the patient’s
clinical data files apart from the laboratory results files
until the study was completed.
Follow-up
After the initial assessment, patients were followed-up
for an average of 22.3 months (range 8 to 30 months). End
points were first fatal and nonfatal cardiovascular events.
Outcome was recorded by the nephrologists, who were
unaware of the results of the laboratory until the final
study. This information always included study and hospi-
talization records. All cardiovascular events were verified
by clinicians not involved in the study, and all patients
were admitted to the hospital during cardiac events. The
patients who started with hemodialysis were censored for
outcome cardiovascular events.
Cardiovascular events were sudden death, acute my-
ocardial infarction based on the Consensus Document of
the Joint ESC/ACC Committee for redefinition of my-
ocardial infarction [7], newly observed unstable angina
pectoris, requirement for coronary bypass surgery or an-
gioplasty, CHF, severe arrhythmia documented by ECG,
stroke, and stenosis of the major arteries of the lower
limbs proven angiographically or sonographically.
Statistical analysis
Values were expressed as mean ± SD or median (in-
terquartile range). Kolmogorov-Smirnov test was used
for analyzing the normality of the distribution of the pa-
rameters. We assessed baseline differences between pa-
tients who suffered a cardiovascular event and those who
did not using the chi-square test and t test for univariate
analysis for normally distributed variables, and Mann-
Whitney U test for skewed variables.
The prognostic power of different factors for cardiovas-
cular events was analyzed by introducing into the models
all covariates related (P < 0.1) to cardiovascular events.
Hazard ratios and their 95% confidence intervals (CI)
were calculated using estimated regression coefficients
(B) and their standard errors (SE) in the Cox regres-
sion multivariate analysis. Analyses were performed us-
ing SPSS, Inc. statistical software (Chicago, IL, USA).
RESULTS
One hundred and twenty-eight patients (78 male, 50
female) with a median age of 70 years (58.2–81.7) and
mean of GFR of 34.8 ± 13.6 mL/min were studied.
Demographic and cardiovascular characteristics of the
patients are shown in Table 1. Five patients were lost to
follow-up, and 5 patients were included in hemodialysis.
Seven patients died, 4 of them from cardiovascular causes,
2 from tumoral causes, and another from a casual acci-
dent. Cardiac events developed in 27 patients, including 4
who died from a cardiovascular cause. The cardiovascular
events were: 2 sudden deaths, 5 myocardial infarctions,
3 cases of angina pectoris, 1 stroke, 2 complete atrial-
ventricular blocks, 5 thromboses of major artery of the
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Table 1. Epidemiologic and analytical characteristics of patients
included in the study
Age years 70 (58.2–81.7)
Gender M/F 78/50
Smoking yes/no 40/88
GFR mL/min 34.8 ± 13.6
Hemoglobin g/dL 13.2 ± 1.7
Albumin g/L 3.9 ± 0.3
Total cholesterol mg/dL 208.2 ± 41.4
LDL/HDL-cholesterol mg/dL 128.8 ± 36.8/57.5 ± 21.0
Statin use yes/no 47/81
Ca-P product 32.7 ± 7.1




Pulse pressure mm Hg 78.6 ± 20.2
Previous CHD yes/no 28/100
Microalbuminuria yes/no 71/57
CHF yes/no 23/105
Cerebrovascular disease yes/no 20/108
PVD yes/no 18/110
10-year CHD risk % 15.5 ± 8.2
Abbreviations are: GFR, glomerular filtrate rate; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; Ca-P product, calcium-phosphate
product; BMI, body mass index; LVH, left ventricular hypertrophy; cTnT,
cardiac troponin T; CHD, coronary heart disease; CHF, chronic heart failure;
PVD, peripheral vascular disease; 10-year CHD risk (%), prediction of a 10-year
risk of coronary heart disease. Values are expressed as mean ± SD or median
(interquartile range) as appropriate.
aHigh cTnT level >0.01 ng/mL.
lower limbs requiring surgical bypass, and 9 episodes of
CHF.
Those patients who suffered from a cardiovascular
event were older (P = 0.002), with lower GFR (P =
0.035), higher pulse pressure (P = 0.011), more anemia
(P = 0.014), higher cTnT levels (P = 0.000), and higher
10-year CHD risk scores (P = 0.006) than those who did
not develop any cardiovascular event (Table 2). In ad-
dition, these patients had higher prevalence of diabetes
mellitus (P = 0.013), previous CHD (P = 0.008), CHF
(P = 0.0000), PVD (P = 0.009), and LVH (P = 0.001)
(Table 2). No differences in albuminuria, total choles-
terol, HDL and LDL-cholesterol, calcium-phosphate
product, iPTH values, and serum albumin were found.
In multivariate Cox regression analysis, the indepen-
dent predictive factors for cardiovascular events were age
[HR 1.07 (1.01–1.14)], previous CHD [HR 4.08 (1.7–9.5)],
P = 0.0012, and cTnT levels [HR 1.64 (1.37–1.96)], P =
0.0000 (Table 3).
DISCUSSION
CVD is the leading cause of death in CKD popula-
tions. In an era when CVD mortality has been declining
in the general population, no such reduction in mortal-
ity has been noted for CKD patients in whom mortality
from cardiovascular causes has progressively increased
and which now represents 50% of all deaths [1, 2].
Table 2. Comparison of those patients who suffered a cardiovascular
event with those who did not
With events Without events
(N = 27) (N = 101) P value
Age years 76 (65–87) 67 (56–78) 0.002
GFR mL/min 29.9 ± 13.7 36.1 ± 13.3 0.035
LVH yes/no 11/16 17/84 0.001
CTnT level high/normala 13/14 7/94 0.000
Diabetes yes/no 14/13 27/74 0.013
Pulse pressure mm Hg 78.6 ± 20.2 67.4 ± 20.0 0.011
Previous CHD yes/no 11/16 17/84 0.008
Hemoglobin g/dL 12.5 ± 1.8 13.4 ± 1.6 0.014
CHF yes/no 14/13 9/92 0.0000
PVD yes/no 8/19 10/91 0.009
10-year CHD risk % 19.6 ± 7.0 14.0 ± 8.2 0.006
No differences were found in the rest of variables. Mean ± SD or median
(interquartile range) as appropriate.
aHigh cTnT level >0.01 ng/mL.
Table 3. Cox Regression multivariate analysis for cardiovascular
morbid events
Hazard ratio
B SE (95% CI) P value
cTnT levels 0.495 0.092 1.64(1.37–1.96) 0.0000
Age 0.074 0.031 1.07 (1.01–1.14) 0.0203
Coronary artery disease 1.407 0.434 4.08(1.7–9.5) 0.0012
Abbreviations are: B, regression coefficient; SE, standard error; CI, confidence
interval.
In this cross-sectional study of patients with moder-
ate CKD, CVD was highly prevalent (22% CHD, 18%
CHF, 16% cerebrovascular disease, and 14% PVD). The
current study suggested that traditional risk factors and
markers such as age, diabetes, LVH, previous CHD,
higher pulse pressure, and previous CHF were related
with the risk of suffering a cardiovascular event. In addi-
tion, anemia, worsening renal function, and higher cTnT
levels also were associated with higher cardiovascular
risk.
We have found that known cardiovascular risk factors
such as hyperlipidemia and albuminuria were not associ-
ated with increasing cardiovascular risk. Also, other fac-
tors such as hypoalbuminemia and calcium-phosphate
product alterations were not related with cardiovascu-
lar morbidity. An explanation of these results could be
that the patients included in the study were stable with-
out lower albumin levels or severe calcium-phosphate
alterations.
Cardiovascular complications represent a fundamen-
tal factor limiting survival in patients with advanced renal
disease [1, 2]. In this perspective, it is important to iden-
tify and validate new simple indicators that reflect risk
associated with cardiac ischemia.
In the present study, we showed that increased cTnT
level is a potent and independent predictor of cardiovas-
cular events in patients with moderate CKD. Two other
traditional factors, age and previous history of CHD, also
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independently predicted cardiovascular events in this
population. These data are similar to other studies per-
formed in hemodialysis patients [8]. Recently, Wood et al
showed that cTnT predicts survival and vascular disease
in patients with chronic renal impairment [9]. However,
the subjects of this study had advanced renal disease, and
only one patient was not on renal replacement therapy at
the end of the study [9]. DeFilippi et al have demonstrated
that in hemodialysis patients without ischemic symptoms,
levels of cTnT and CRP independently identify patients
at risk of death, and the combination of the 2 parameters
identify patients at particularly high risk [10]. Unfortu-
nately, we do not have sufficient CRP data available to
analyze in this study. Furthermore, these authors showed
that even small elevations of cTnT concentration, at lev-
els lower than those traditionally used for the diagnosis
of acute coronary syndromes, were associated with an
increased likelihood of multivessel coronary artery dis-
ease in stable patients on hemodialysis [10]. Therefore,
slight elevations of cTnT could be indicative of unde-
tected coronary artery disease.
CONCLUSION
Age, previous CHD, and cTnT levels independently
predict cardiovascular risk in stable patients with mod-
erate CKD. cTnT could help identify those patients with
a higher risk of cardiovascular disease, and select those
patients who would subsequently benefit from CHD
screening.
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